Inhibitex, biopharmaceutical company developing products that can treat, prevent or diagnose serious infections, has licensed a number of Hepatitis C inhibitors from Cardiff University in the United Kingdom.

Inhibitex (Nasdaq: INHX) paid an upfront license fee and agreed to future milestone payments as well as royalties on any drug sales. However, specifics of the agreement were not disclosed.

The compounds were discovered at the U.K. University and a university in the Netherlands.